SOPHiA GENETICS (NASDAQ:SOPH) Director Kathy Hibbs Sells 6,250 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $8.13, for a total value of $50,812.50. Following the sale, the director owned 96,992 shares in the company, valued at $788,544.96. The trade was a 6.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Price Performance

SOPH opened at $7.61 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $638.40 million, a P/E ratio of -6.62 and a beta of 0.98. The stock has a 50-day moving average price of $6.98 and a 200-day moving average price of $5.67. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The firm had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Equities analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the company. Maven Securities LTD bought a new stake in shares of SOPHiA GENETICS in the second quarter worth about $866,000. AXQ Capital LP purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $119,000. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter worth approximately $9,809,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 2nd quarter worth approximately $567,000. Finally, Royal Bank of Canada grew its position in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SOPH has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright boosted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, BTIG Research increased their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.